Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American Journal of Transplantation

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1600-6143.2007.02133.xPMID 18261177
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical proteomics: A need to define the field and to begin to set adequate standards

  2007cited by this paper
• Cytomegalovirus in transplantation – challenging the status quo

  2007cited by this paper
• Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.

  2006cited by this paper
• Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients

  2006cited by this paper
• Benefits of Cytomegalovirus Prophylaxis in Solid Organ Transplantation

  2006cited by this paper
• American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation

  2006cited by this paper
• Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.

  2006influential reference
• Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation.

  2006cited by this paper
• Messenger RNA for FOXP3 in the urine of renal-allograft recipients.

  2005cited by this paper
• Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: Towards new diagnostic and therapeutic approaches

  2005cited by this paper
• Rejection--more than the eye can see.

  2005cited by this paper
• Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients

  2005cited by this paper
• Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

  2005cited by this paper
• Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy.

  2005cited by this paper
• Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes.

  2004cited by this paper
• Cytomegalovirus Prophylaxis and Graft Outcome in Solid Organ Transplantation: A Collaborative Transplant Study Report

  2004cited by this paper
• Risk Factors for Cytomegalovirus Viremia and Disease Developing after Prophylaxis in High-Risk Solid-Organ Transplant Recipients

  2004cited by this paper
• Guidelines for the prevention and management of infectious complications of solid organ transplantation

  2004cited by this paper
• The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models

  2004cited by this paper
• Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.

  2004influential reference
• Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching.

  2003cited by this paper
• The Impact of Cytomegalovirus Infection and Disease on Rejection Episodes in Renal Allograft Recipients

  2002cited by this paper
• High Variability between Results of Different In-House Tests for Cytomegalovirus (CMV) Monitoring and a Standardized Quantitative Plasma CMV PCR Assay

  2002cited by this paper
• Viral infections and their impact on chronic renal allograft dysfunction.

  2001cited by this paper
• Prophylaxis for CMV should not now replace pre‐emptive therapy in solid organ transplantation

  2001influential reference
• Prophylaxis for CMV should now replace pre‐emptive therapy in solid organ transplantation

  2001influential reference
• Polycystin-1 interacts with E-cadherin and the catenins--clues to the pathogenesis of cyst formation in ADPKD?

  2000cited by this paper
• European Best Practice Guidelines for Renal Transplantation (part 1).

  2000cited by this paper
• Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses

  2000cited by this paper
• A PROSPECTIVE STUDY OF THE NATURAL COURSE OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL ALLOGRAFT RECIPIENTS1

  2000cited by this paper
• Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

  1999cited by this paper
• Evaluation of New Quantitative Assays for Diagnosis and Monitoring of Cytomegalovirus Disease in Human Immunodeficiency Virus-Positive Patients

  1999cited by this paper
• CLINICAL COURSE OF CYTOMEGALOVIRUS (CMV) VIREMIA WITH AND WITHOUT GANCICLOVIR TREATMENT IN CMV-SEROPOSITIVE RENAL TRANSPLANT RECIPIENTS: LONGITUDINAL STUDY OF CMV PP65 ANTIGENEMIA ASSAY

  1998cited by this paper
• Clinical Course of Cytomegalovirus (CMV) Viremia with and without Ganciclovir Treatment in CMV-Seropositive Kidney Transplant Recipients

  1998cited by this paper
• Does cytomegalovirus cause glomerular injury in renal allograft recipients?

  1997cited by this paper
• Cytomegalovirus infections following renal transplantation – effects of antiviral prophylaxis: a report of the North American Pediatric Renal Transplant Cooperative Study

  1997cited by this paper
• Diagnostic markers and risk factors of cytomegalovirus infection and disease in renal allograft recipients.

  1995cited by this paper
• Impact of cytomegalovirus infection on organ transplant recipients.

  1990cited by this paper
• CYTOMEGALOVIRUS INFECTION COMPLICATING RENAL TRANSPLANTATION AND ITS RELATIONSHIP TO ACUTE TRANSPLANT GLOMERULOPATHY

  1988cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Adoptive γδ T cell therapy controls cytomegalovirus infection in preclinical transplantation models.

  2026cites this paper
• CMV prevention in heart transplant recipients: Comparative analysis of preemptive and prophylactic strategies

  2026cites this paper
• [Strategies for the diagnosis and monitoring of cytomegalovirus in transplant patients].

  2025cites this paper
• Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in CMV-seronegative recipients of CMV-seropositive donor kidneys Post hoc analysis of a randomized, phase 3 trial of letermovir versus valganciclovir prophylaxis.

  2025cites this paper
• “Cytomegalovirus Infection in Renal Transplant Recipients: Incidence, Risk Factors, Clinical Profile and Outcomes”

  2025cites this paper
• Clinical and Economic Burden Associated With Anti-Cytomegalovirus (CMV) Prophylaxis Therapies in Adult Kidney Transplant Recipients (LECOCYT): An Observational Study

  2025cites this paper
• Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.

  2025cites this paper
• The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation

  2025cites this paper
• Cytomegalovirus Matching in Deceased Donor Kidney Allocation: Results From a U.S. National Simulation Model

  2024cites this paper
• Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults

  2024cites this paper
• Prevention and management of cytomegalovirus infection and disease in kidney transplant: A consensus statement of the Transplantation Society of Taiwan.

  2024cites this paper
• Posttransplant complications: molecular mechanisms and therapeutic interventions

  2024cites this paper
• Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation

  2024influential citation
• Pre-Transplant Frequencies of FoxP3+CD25+ in CD3+CD8+ T Cells as Potential Predictors for CMV in CMV-Intermediate Risk Kidney Transplant Recipients

  2024cites this paper
• Low-Dose vs Standard-Dose Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplantation: A Single-Center Retrospective Analysis.

  2024cites this paper
• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.

  2024cites this paper
• The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation

  2024influential citation
• Prophylactic vs preemptive strategy for the prevention of CMV disease in solid organ transplant recipients: systematic review and meta-analysis of randomized controlled trials

  2024cites this paper
• High seroprevalence of CMV among Algerian hemodialysis patients and the general population: Intermediate-risk patients for post-transplant CMV infection.

  2024cites this paper
• Prevention and management of CMV infection in pediatric solid organ transplant recipients

  2023cites this paper
• Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023

  2023cites this paper
• A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients

  2023cites this paper
• Preemptive therapy versus universal prophylaxis: Time for reconciliation?

  2023cites this paper
• Relationship between Cytomegalovirus Viremia and Long-Term Outcomes in Kidney Transplant Recipients with Different Donor Ages

  2023cites this paper
• Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management

  2023cites this paper
• A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients

  2023cites this paper
• Renal allograft survival: Incidence and risk factors associated with graft dysfunction

  2023cites this paper
• Cytomegalovirus Exposure and the Risk of Overall Infection After Kidney Transplantation: A Cohort Study on the Indirect Effects Attributable to Viral Replication

  2022cites this paper
• Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021

  2022cites this paper
• Murine cytomegalovirus promotes renal allograft inflammation via Th1/17 cells and IL‐17A

  2022cites this paper
• Prophylaxis of Cytomegalovirus Infection in Solid Organ Transplantation, Retrospective Evaluation

  2022cites this paper
• Laboratory diagnostic testing for cytomegalovirus infection in solid organ transplant patients

  2022cites this paper
• Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review

  2021cites this paper
• Cytomegalovirus en transplantation rénale : traitement préventif ou préemptif et nouvelles alternatives

  2021cites this paper
• Individualized management of cytomegalovirus in solid organ transplant recipients

  2021influential citation
• Viral infections in lung transplantation

  2021cites this paper
• Assessment of Risk Factors and Outcome of Early Versus Late Cytomegalovirus Infection Infection in Living-related D+/R + Renal Allograft Recipients

  2021cites this paper
• Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update

  2021cites this paper
• Late‐onset allograft rejection, cytomegalovirus infection, and renal allograft loss: Is anti‐CMV prophylaxis required following late‐onset allograft rejection?

  2021cites this paper
• Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategy.

  2021cites this paper
• Urinary Tract Infections: Virus

  2021cites this paper
• Evaluation of cytomegalovirus prophylaxis in low and intermediate risk kidney transplant recipients receiving lymphocyte‐depleting induction

  2021cites this paper
• The burden of cytomegalovirus infection remains high in high‐risk kidney transplant recipients despite six‐month valganciclovir prophylaxis

  2021cites this paper
• Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients

  2021cites this paper
• Cytomegalovirus infection in kidney transplant patients: Prevalence, risk factors, and impact on outcome - A local multicentre experience.

  2021cites this paper
• The Interferon-Gamma +874 A/T Polymorphism Is Not Associated With CMV Infection After Kidney Transplantation

  2020cites this paper
• Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.

  2020cites this paper
• Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial.

  2020cites this paper
• Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for hematological disease: systematic review and meta-analysis.

  2020cites this paper
• Among CMV‐positive renal transplant patients receiving non‐T‐cell depleting induction, the absence of CMV disease prevention is a safe strategy: A retrospective cohort of 372 patients

  2020cites this paper
• Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention.

  2020cites this paper
• Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: A systematic review of randomized controlled trials.

  2020cites this paper
• Sex-Associated Differences in Cytomegalovirus Prevention: Prophylactic Strategy is Potentially Associated With a Strong Kidney Function Impairment in Female Renal Transplant Patients

  2020cites this paper
• Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers

  2020cites this paper
• Cytomegalovirus in Solid Organ Transplant Recipients: Prevention, Diagnosis, and Treatment

  2020cites this paper
• ESITRA-SEIMC / REIPI recommendations for the management of cytomegalovirus nfection in solid-organ transplant patients

  2019cites this paper
• Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus–positive kidney transplant recipient

  2019cites this paper
• Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.

  2019cites this paper
• A critical review of the relationship between post-transplant atherosclerotic events and cytomegalovirus exposure in kidney transplant recipients

  2019cites this paper
• Characterization of the dynamics of human cytomegalovirus resistance to antiviral drugs by ultra-deep sequencing.

  2019cites this paper
• Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

  2019cites this paper
• Sex-associated differences in cytomegalovirus prevention: Prophylactic strategy is associated with a strong kidney function impairment in female renal transplant patients

  2019cites this paper
• Cytomegalovirus renal infection: Rare manifestation of a common post‐transplant viral infection—A case series

  2019cites this paper
• Risk-stratified approach to anti-viral prophylaxis against cytomegalovirus disease in glomerulonephritis and renal vasculitis treated with potent immunosuppressants

  2019cites this paper
• Impact of standardized protocols for cytomegalovirus disease prevention in pediatric solid organ transplant recipients

  2019cites this paper
• Universal prophylaxis with valganciclovir versus preemptive therapy in minimizing the risk of cytomegalovirus infection and disease in high-risk and intermediate-risk kidney transplant recipients: a single-center experience

  2019cites this paper
• Efficacy of Ultralow-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in ABO-Incompatible Kidney Transplantation Recipients.

  2018cites this paper
• Comparison of universal prophylaxis and preemptive approach for cytomegalovirus associated outcome measures in renal transplant patients: A meta‐analysis of available data

  2018influential citation
• NK cell and Th17 responses are differentially induced in murine cytomegalovirus infected renal allografts and vary according to recipient virus dose and strain

  2018cites this paper
• Risk-guided strategy to prevent cytomegalovirus associated complications after liver transplantation

  2018cites this paper
• Infection in Kidney Transplantation

  2018cites this paper
• Effect of Low-Dose Vs Standard-Dose Valganciclovir in the Prevention of Cytomegalovirus Disease in Kidney Transplantation Recipients: A Systemic Review and Meta-Analysis.

  2018cites this paper
• Contemporary Kidney Transplantation

  2018cites this paper
• Cytomegalovirová a polyomavirová infekce po transplantaci ledviny

  2018cites this paper
• Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives

  2018cites this paper
• Common viral infections in kidney transplant recipients

  2018cites this paper
• Impact of High‐Dose Acyclovir Cytomegalovirus Prophylaxis Failure in Abdominal Solid Organ Transplant Recipients

  2018cites this paper
• Low‐dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti‐thymocyte globulin

  2018cites this paper
• A high level of urinary retinol-binding protein is associated with cytomegalovirus infection in kidney transplantation.

  2018cites this paper
• Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial

  2017cites this paper
• Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.

  2017cites this paper
• Biologics in Transplantation (Anti-thymocyte Globulin, Belatacept, Alemtuzumab): How Should We Use Them?

  2017cites this paper
• Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy

  2017cites this paper
• Cytomegalovirus infection after kidney transplantation and long-term graft loss

  2017cites this paper
• Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study

  2017cites this paper
• Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms

  2017cites this paper
• Technology Medicine Open Access book

  2017cites this paper
• Infection du donneur par le CMV et transplantation rénale : impact sur la réponse immunitaire spécifique et sur la survie des greffons

  2017cites this paper
• Cytomegalovirus infection after kidney transplantation and long-term graft loss.

  2017cites this paper
• Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.

  2017cites this paper
• Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.

  2017cites this paper
• Indirect effects of cytomegalovirus in kidney transplantation

  2017cites this paper
• Outcome of pediatric renal transplantation in urological versus non-urological causes of end stage renal disease: Does it matter?

  2017cites this paper
• Title Reinfection of cytomegalovirus in renal transplantation

  2017cites this paper
• The Impact of Viral Load and Time to Onset of Cytomegalovirus Replication on Long-Term Graft Survival after Kidney Transplantation

  2017cites this paper
• Gastrointestinal Side Effects of Post-Transplant Therapy.

  2016cites this paper
• Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes

  2016cites this paper
• Expanding role of cytomegalovirus as a human pathogen

  2016cites this paper
• Two strategies for prevention of cytomegalovirus infections after liver transplantation.

  2016cites this paper
• Enfermedades Infecciosas y Microbiología Clínica

  2016cites this paper